ATE184480T1 - Verfahren zur herstellung von arzneizubereitungen mit verzögerter wirkstoffabgabe - Google Patents

Verfahren zur herstellung von arzneizubereitungen mit verzögerter wirkstoffabgabe

Info

Publication number
ATE184480T1
ATE184480T1 AT94304933T AT94304933T ATE184480T1 AT E184480 T1 ATE184480 T1 AT E184480T1 AT 94304933 T AT94304933 T AT 94304933T AT 94304933 T AT94304933 T AT 94304933T AT E184480 T1 ATE184480 T1 AT E184480T1
Authority
AT
Austria
Prior art keywords
water
soluble polypeptide
active ingredients
delayed release
medicinal preparations
Prior art date
Application number
AT94304933T
Other languages
English (en)
Inventor
Yasutaka Igari
Kazumichi Yamamoto
Kayoko Okamoto
Yutaka Yamagata
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE184480T1 publication Critical patent/ATE184480T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94304933T 1993-07-05 1994-07-05 Verfahren zur herstellung von arzneizubereitungen mit verzögerter wirkstoffabgabe ATE184480T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP16579393 1993-07-05
JP8176594 1994-04-20

Publications (1)

Publication Number Publication Date
ATE184480T1 true ATE184480T1 (de) 1999-10-15

Family

ID=26422772

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94304933T ATE184480T1 (de) 1993-07-05 1994-07-05 Verfahren zur herstellung von arzneizubereitungen mit verzögerter wirkstoffabgabe

Country Status (11)

Country Link
US (1) US5534269A (de)
EP (1) EP0633020B1 (de)
KR (1) KR950002748A (de)
CN (1) CN1106653A (de)
AT (1) ATE184480T1 (de)
AU (1) AU674077B2 (de)
CA (1) CA2127317C (de)
DE (1) DE69420632T2 (de)
FI (1) FI943205L (de)
NO (1) NO942515L (de)
NZ (1) NZ260909A (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6790439B1 (en) * 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
WO1997001331A2 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
AU710347B2 (en) * 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
DK0889722T3 (da) * 1996-03-28 2003-02-10 Takeda Chemical Industries Ltd Præparat med forsinket frigivelse og fremstilling deraf
DE69719367T2 (de) * 1996-12-20 2003-10-16 Takeda Chemical Industries, Ltd. Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
WO1999037288A1 (en) * 1998-01-21 1999-07-29 Takeda Chemical Industries, Ltd. Lyophilization method for sustained-release preparations
WO1999048519A1 (en) 1998-03-20 1999-09-30 Takeda Chemical Industries, Ltd. Sustained-release preparation of physiologically active polypeptide and production thereof
FR2778847A1 (fr) * 1998-05-20 1999-11-26 Jean Pierre Perraud Implant injectable en sous gingival resorbable, constitue de microspheres a liberation prolongee et chargees en principes actifs et en suspension dans un gel vecteur
US6165509A (en) * 1998-09-01 2000-12-26 University Of Washington Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
FR2793684B1 (fr) * 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
ATE389414T1 (de) 1999-09-08 2008-04-15 Chugai Pharmaceutical Co Ltd Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben
CN1384751A (zh) * 1999-09-17 2002-12-11 武田药品工业株式会社 蛋白粉生产方法
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
KR20030027077A (ko) * 2000-09-01 2003-04-03 쥬가이 세이야쿠 가부시키가이샤 장기 안정화 용액 제제
WO2002053136A1 (en) * 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Sustained release preparations
DK1397155T3 (en) 2001-06-21 2015-12-07 Genentech Inc Prolonged release formulation
TWI225416B (en) 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
US20050064039A1 (en) * 2001-12-26 2005-03-24 Tomomichi Futo Novel microsphere and method for production thereof
US8519008B2 (en) 2003-01-22 2013-08-27 Purina Animal Nutrition Llc Method and composition for improving the health of young monogastric mammals
BRPI0409032A (pt) 2003-04-10 2006-05-02 Pr Pharmaceuticals método para a produção de micropartìculas à base de emulsão
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
JP2006523683A (ja) * 2003-04-15 2006-10-19 オッパーバス・ホールディング・ビー・ブイ タンパク質及び／またはポリペプチド及びコロイド粒子を含む医薬組成物
CN102935069A (zh) * 2003-07-15 2013-02-20 Pr药品有限公司 控释组合物的制备方法
US8900636B2 (en) * 2003-07-23 2014-12-02 Evonik Corporation Controlled release compositions
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
DE102004046102B4 (de) 2004-09-23 2009-09-03 Mars Inc. Indikatorgranulat
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CN101199623B (zh) * 2006-12-16 2011-04-27 石茂光 治疗高血压药物缓控释制剂的制备方法
WO2008143992A2 (en) * 2007-05-18 2008-11-27 Durect Corporation Improved depot formulations
JP2010531807A (ja) 2007-05-25 2010-09-30 トルマー セラピューティクス， インコーポレイテッド リスペリドン化合物の徐放送達製剤
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
JP2016512523A (ja) 2013-03-11 2016-04-28 デュレクト コーポレーション 高粘性液体キャリアを含む注射用制御放出組成物
CN104288123B (zh) * 2014-10-27 2016-09-14 浙江理工大学 一种负载干扰素微胶囊的制备方法
CN110404115B (zh) * 2019-07-23 2022-03-18 广东省医疗器械研究所 一种具有表面坑洞的碳酸盐/可降解高分子微球及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
JP3116311B2 (ja) * 1990-06-13 2000-12-11 エーザイ株式会社 マイクロスフィアの製法
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5171579A (en) * 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
US5470582A (en) * 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles

Also Published As

Publication number Publication date
CN1106653A (zh) 1995-08-16
NO942515D0 (no) 1994-07-04
FI943205A7 (fi) 1995-01-06
CA2127317A1 (en) 1995-01-06
DE69420632D1 (de) 1999-10-21
DE69420632T2 (de) 2000-03-02
NO942515L (no) 1995-01-06
FI943205L (fi) 1995-01-06
EP0633020B1 (de) 1999-09-15
AU674077B2 (en) 1996-12-05
KR950002748A (ko) 1995-02-16
AU6614594A (en) 1995-01-12
NZ260909A (en) 1995-04-27
FI943205A0 (fi) 1994-07-05
CA2127317C (en) 2008-10-07
EP0633020A1 (de) 1995-01-11
US5534269A (en) 1996-07-09

Similar Documents

Publication Publication Date Title
ATE184480T1 (de) Verfahren zur herstellung von arzneizubereitungen mit verzögerter wirkstoffabgabe
EP0158277A3 (de) Implantierbare Zubereitungen von regulatorischen Peptiden mit gesteuerter Freisetzung und Verfahren zur ihrer Herstellung
ATE101340T1 (de) Neue arzneimittelformulierung sowie verfahren zu deren herstellung.
ATE178616T1 (de) Verfahren zur herstellung von biologisch aktivem protein (z.b. tgf)
DE3481170D1 (de) Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung.
DE69704426D1 (de) Verfahren zur herstellung von medizinischem kaugummi mit einem guten geschmack, enthaltend eine einschlussverbindung
ATA151587A (de) Verfahren zur herstellung einer pharmazeutischen kapsel zur oralen verabreichung mit verzögerter wirkstofffreisetzung bzw. kombinierter verzögerter/rascher wirkstofffreisetzung
DK0436370T3 (da) Farmaceutisk præparat til kontrolleret afgivelse og fremgangsmåde til fremstilling deraf
DE3872382D1 (de) Pharmazeutische zusammensetzungen mit verlaengerter wirkung und verfahren zu ihrer herstellung.
DE3483175D1 (de) Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung.
DE69025920D1 (de) Glykosaminoglykan-modifiertes Protein, Verfahren zu dessen Herstellung und pharmazeutische Zubereitungen, die es enthalten
ATE149826T1 (de) Verfahren zur herstellung von festen pharmazeutischen retardformen
DE69129899D1 (de) Verfahren zur Herstellung von D-Alpha-Aminosäuren
ATE230274T1 (de) Physiologisch aktives polypeptid enthaltende zubereitung mit verzögerter freisetzung und deren herstellung
DE69009237D1 (de) Verfahren zur Herstellung von optisch aktiven Estern der 6-t-Butoxy-3,5-dihydroxyhexansäure.
FR2768341B1 (fr) Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides
DE68924011D1 (de) Verfahren zur Herstellung von Pyrazolkarbonsäure und Derivaten.
DE68917937D1 (de) Verbindungen mit magensäureinhibitorwirkung und verfahren zur herstellung.
DE69808938D1 (de) Verfahren zur herstellung von pharmazeutischen zusammensetzungen
ATE160588T1 (de) Aus bakteriellen proteinen bestehender extrakt, verfahren zur dessen herstellung und diesen extrakt enthaltende pharmazeutische zusammensetzung
ATE103913T1 (de) Verfahren und zwischenprodukte zur herstellung von oxophthalazinyl-essigsaeuren und deren analogen.
DE68915310D1 (de) Verfahren zur Herstellung von enantiomerischen homogenen Aminopyrrolidinyl-naphthyridin- und Quinoloncarbonsäuren.
DE59604613D1 (de) Verfahren zur herstellung von optisch aktiven alpha-aminosäuren und alpha-aminosäure-derivaten
ATE88632T1 (de) Verfahren zur herstellung waessriger mischmicelloesungen.
DE58908961D1 (de) Verfahren zur Isolierung von 2-Keto-polyhydroxy-C6-carbonsäuren, insbesondere von 2-Keto-L-gulonsäure aus wässrigen Fermentationsausträgen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties